Search Results - "Jenkins, Laura J"

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer by Weickhardt, Andrew J, Lau, David K, Hodgson-Garms, Margeaux, Lavis, Austen, Jenkins, Laura J, Vukelic, Natalia, Ioannidis, Paul, Luk, Ian Y, Mariadason, John M

“…Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinomas and confer sensitivity to FGFR…”
Get full text

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles by Meka, Anand Kumar, Jenkins, Laura J, Dàvalos-Salas, Mercedes, Pujara, Naisarg, Wong, Kuan Yau, Kumeria, Tushar, Mariadason, John M, Popat, Amirali

“…Suberoylanilide hydroxamic acid (SAHA) or vorinostat (VOR) is a potent inhibitor of class I histone deacetylases (HDACs) that is approved for the treatment of…”
Get full text

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma by Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Jenkins, Laura J., Poh, Ashleigh R., Walkiewicz, Marzena, Leong, Trishe, Mariadason, John M., Cebon, Jonathan, Balachander, Srividya B., Cidado, Justin R., Lee, Erinna F., John, Thomas, Fairlie, Walter D.

“…Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs…”
Get full text

BECLIN1 is essential for intestinal homeostasis involving autophagy-independent mechanisms through its function in endocytic trafficking by Tran, Sharon, Juliani, Juliani, Harris, Tiffany J., Evangelista, Marco, Ratcliffe, Julian, Ellis, Sarah L., Baloyan, David, Reehorst, Camilla M., Nightingale, Rebecca, Luk, Ian Y., Jenkins, Laura J., Ghilas, Sonia, Yakou, Marina H., Inguanti, Chantelle, Johnson, Chad, Buchert, Michael, Lee, James C., De Cruz, Peter, Duszyc, Kinga, Gleeson, Paul A., Kile, Benjamin T., Mielke, Lisa A., Yap, Alpha S., Mariadason, John M., Fairlie, W. Douglas, Lee, Erinna F.

“…Autophagy-related genes have been closely associated with intestinal homeostasis. BECLIN1 is a component of Class III phosphatidylinositol 3-kinase complexes…”
Get full text

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets by Lau, David K., Mouradov, Dmitri, Wasenang, Wiphawan, Luk, Ian Y., Scott, Cameron M., Williams, David S., Yeung, Yvonne H., Limpaiboon, Temduang, Iatropoulos, George F., Jenkins, Laura J., Reehorst, Camilla M., Chionh, Fiona, Nikfarjam, Mehrdad, Croagh, Daniel, Dhillon, Amardeep S., Weickhardt, Andrew J., Muramatsu, Toshihide, Saito, Yoshimasa, Tebbutt, Niall C., Sieber, Oliver M., Mariadason, John M.

“…Biliary tract cancers (BTCs) currently have no approved targeted therapies. Although genomic profiling of primary BTCs has identified multiple potential drug…”
Get full text

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma by Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. Douglas

Get full text

Aberrant DNA Methylation in Colorectal Cancer: What Should We Target? by Tse, Janson W T, Jenkins, Laura J, Chionh, Fiona, Mariadason, John M

“…Colorectal cancers (CRCs) are characterized by global hypomethylation and promoter-specific DNA methylation. A subset of CRCs with extensive and co-ordinate…”
Get more information

Ehf controls mammary alveolar lineage differentiation and is a putative suppressor of breast tumorigenesis by Nightingale, Rebecca, Reehorst, Camilla M, Vukelic, Natalia, Papadopoulos, Nikolaos, Liao, Yang, Guleria, Shalini, Bell, Caroline, Vaillant, François, Paul, Sudip, Luk, Ian Y, Dhillon, Amardeep S, Jenkins, Laura J, Morrow, Riley J, Jackling, Felicity C, Chand, Ashwini L, Chisanga, David, Chen, Yunshun, Williams, David S, Anderson, Robin L, Ellis, Sarah, Meikle, Peter J, Shi, Wei, Visvader, Jane E, Pal, Bhupinder, Mariadason, John M

“…The transcription factor EHF is highly expressed in the lactating mammary gland, but its role in mammary development and tumorigenesis is not fully understood…”
Get more information

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK by Lau, David K, Luk, Ian Y, Jenkins, Laura J, Martin, Andrew, Williams, David S, Schoffer, Kael L, Chionh, Fiona, Buchert, Michael, Sjoquist, Katrin, Boussioutas, Alex, Hayes, Sarah A, Ernst, Matthias, Weickhardt, Andrew J, Pavlakis, Nick, Tebbutt, Niall C, Mariadason, John M

“…Amplification or overexpression of the FGFR family of receptor tyrosine kinases occurs in a significant proportion of gastric cancers. Regorafenib is a…”
Get full text

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death by Jenkins, Laura J, Luk, Ian Y, Fairlie, W Douglas, Lee, Erinna F, Palmieri, Michelle, Schoffer, Kael L, Tan, Tao, Ng, Irvin, Vukelic, Natalia, Tran, Sharon, Tse, Janson W T, Nightingale, Rebecca, Alam, Zakia, Chionh, Fiona, Iatropoulos, George, Ernst, Matthias, Afshar-Sterle, Shoukat, Desai, Jayesh, Gibbs, Peter, Sieber, Oliver M, Dhillon, Amardeep S, Tebbutt, Niall C, Mariadason, John M

“…The EGFR/RAS/MEK/ERK signaling pathway (ERK/MAPK) is hyperactivated in most colorectal cancers. A current limitation of inhibitors of this pathway is that they…”
Get full text

Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression by Luk, Ian Y., Jenkins, Laura J., Schoffer, Kael L., Ng, Irvin, Tse, Janson W. T., Mouradov, Dmitri, Kaczmarczyk, Stanislaw, Nightingale, Rebecca, Burrows, Allan D., Anderson, Robin L., Arango, Diego, Dopeso, Higinio, Croft, Larry, Richardson, Mark F., Sieber, Oliver M., Liao, Yang, Mooi, Jennifer K., Vukelic, Natalia, Reehorst, Camilla M., Afshar-Sterle, Shoukat, Whitehall, Vicki L. J., Fennell, Lochlan, Abud, Helen E., Tebbutt, Niall C., Phillips, Wayne A., Williams, David S., Shi, Wei, Mielke, Lisa A., Ernst, Matthias, Dhillon, Amardeep S., Clemons, Nicholas J., Mariadason, John M.

“…Colorectal cancers (CRCs) often display histological features indicative of aberrant differentiation but the molecular underpinnings of this trait and whether…”
Get full text

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer by Jenkins, Laura J., Luk, Ian Y., Chionh, Fiona, Tan, Tao, Needham, Kristen, Ayton, Jamieson, Reehorst, Camilla M., Vukelic, Natalia, Sieber, Oliver M., Mouradov, Dmitri, Gibbs, Peter, Williams, David S., Tebbutt, Niall C., Desai, Jayesh, Hollande, Frédéric, Dhillon, Amardeep S., Lee, Erinna F., Merino, Delphine, Fairlie, W. Douglas, Mariadason, John M.

“…Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAF V600E…”
Get full text

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma by Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. D.

“…Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a…”
Get full text

Abstract 2492: BRAF inhibitors synergize with BH3 mimetics to induce apoptosis in BRAF mutant colorectal cancer cells by Jenkins, Laura J., Chionh, Fiona, Luk, Ian Y., Lee, Erinna F., Dhillon, Amardeep S., Tebbutt, Niall, Fairlie, Walter D., Mariadason, John M.

“…Abstract Activating mutations in BRAF (BRAFV600E) occur in ~10% of colorectal cancers (CRCs) and drive tumorigenesis through constitutive activation of MAPK…”
Get full text

Abstract 3089: Combining MEK and HDAC inhibitors as a therapeutic strategy to promote differentiation of colorectal cancer by Jenkins, Laura J., Luk, Ian Y., Tse, Janson W., Mooi, Jennifer, Dhillon, Amardeep S., Mariadason, John M.

“…Abstract The five-year survival rate for patients with metastatic colorectal cancer is less than 15%, necessitating an urgent need to develop novel therapeutic…”
Get full text

BCL-X L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer by Jenkins, Laura J, Luk, Ian Y, Chionh, Fiona, Tan, Tao, Needham, Kristen, Ayton, Jamieson, Reehorst, Camilla M, Vukelic, Natalia, Sieber, Oliver M, Mouradov, Dmitri, Gibbs, Peter, Williams, David S, Tebbutt, Niall C, Desai, Jayesh, Hollande, Frédéric, Dhillon, Amardeep S, Lee, Erinna F, Merino, Delphine, Fairlie, W Douglas, Mariadason, John M

“…Metastatic BRAF colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAF inhibitor…”
Get full text

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer by Laura J. Jenkins, Ian Y. Luk, Fiona Chionh, Tao Tan, Kristen Needham, Jamieson Ayton, Camilla M. Reehorst, Natalia Vukelic, Oliver M. Sieber, Dmitri Mouradov, Peter Gibbs, David S. Williams, Niall C. Tebbutt, Jayesh Desai, Frédéric Hollande, Amardeep S. Dhillon, Erinna F. Lee, Delphine Merino, W. Douglas Fairlie, John M. Mariadason

“…Abstract Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the…”
Get full text

Abstract B014: Genotype-tailored ERK/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death by Jenkins, Laura J., Luk, Ian Y., Fairlie, Walter D., Lee, Erinna F., Palmieri, Michelle, Schoffer, Kael L., Tan, Tao, Ng, Irvin, Vukelic, Natalia, Tran, Sharon, Tse, Janson, Nightingale, Rebecca, Alam, Zakia, Chionh, Fiona, Iatropoulos, George, Ernst, Matthias, Afshar-Sterle, Shoukat, Desai, Jayesh, Gibbs, Peter, Sieber, Oliver M., Dhillon, Amardeep S., Tebbutt, Niall C., Mariadason, John M.

“…Abstract The EGFR/RAS/MEK/ERK signaling pathway (ERK/MAPK) is hyper-activated in most colorectal cancers (CRCs). A current limitation of inhibitors of this…”
Get full text